Newport Exploration Ltd. (NWXPF)

Revance Therapeutics Income Statement

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Cost of Revenue	0.04	-	-	-	-	-
Gross Profit	-0.04	-	-	-	-	-
Selling, General & Admin	1.37	1.39	1.47	1.42	1.43	1.37
Operating Expenses	1.72	1.46	1.54	1.47	1.46	1.99
Operating Income	-1.76	-1.46	-1.54	-1.47	-1.46	-1.99
Interest Expense	-0	-0	-0.01	-0	-	-
Interest & Investment Income	0.09	0.09	0.12	0.03	0.06	0.11
Currency Exchange Gain (Loss)	-0	0.01	0.01	-0.04	-0.1	0.03
Other Non Operating Income (Expenses)	2.86	4.2	5.21	9.15	10.52	10.69
Pretax Income	1.18	2.84	3.8	7.66	9.03	8.83
Income Tax Expense	0.51	0.92	1.22	2.4	2.8	2.89
Net Income	0.67	1.92	2.58	5.27	6.23	5.94
Net Income to Common	0.67	1.92	2.58	5.27	6.23	5.94
Net Income Growth	-68.99%	-25.56%	-50.95%	-15.47%	4.91%	5.93%
Shares Outstanding (Basic)	106	106	106	106	105	104
Shares Outstanding (Diluted)	107	106	106	107	106	105
Shares Change (YoY)	1.29%	-	-1.02%	0.17%	1.64%	2.81%
EPS (Basic)	0.01	0.02	0.02	0.05	0.06	0.06
EPS (Diluted)	0.01	0.02	0.02	0.05	0.06	0.06
EPS Growth	-35.00%	-8.95%	-59.90%	-15.65%	3.98%	3.24%
Free Cash Flow	1.13	2.24	4.82	5.46	5.58	7.23
Free Cash Flow Per Share	0.01	0.02	0.05	0.05	0.05	0.07
Dividend Per Share	0.005	0.030	0.040	0.070	0.070	0.020
Dividend Growth	-85.71%	-25.00%	-42.86%	-	250.00%	-
EBITDA	-1.76	-1.45	-1.53	-1.46	-1.45	-1.99
D&A For EBITDA	0	0	0	0	0	0
EBIT	-1.76	-1.46	-1.54	-1.47	-1.46	-1.99
Effective Tax Rate	43.30%	32.27%	32.04%	31.28%	30.98%	32.75%

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.